C60 C61 C62 C63 C64 C65 C66 C67 C68
Conditions
Interventions
Group 1: Patients with genitourinary malignancies (e.g., urothelial carcinoma, renal cell carcinoma) receiving systemic therapy (such as immunotherapy, chemotherapy, or targeted therapy) as part of ro
all treatments are determined by the treating physician according to standard of care.
Sponsors
Urologische Klinik und Poliklinik, LMU Klinikum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of a genitourinary malignancy (ICD C60–C68), including prostate, urothelial, kidney, penile, or testicular cancer Received systemic therapy (e.g., chemotherapy, immunotherapy, targeted therapy, antibody-drug conjugates, or anti-hormonal therapy) Treatment and documentation at a participating university or tertiary care center Availability of sufficient clinical documentation according to the inclusion criteria
Exclusion criteria
Exclusion criteria: Incomplete or inconsistent clinical data Missing essential treatment or follow-up information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS), defined as the time from initiation of systemic therapy to the first documented disease progression (as assessed by the treating physician according to RECIST 1.1) or death from any cause, whichever occurs first. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) Cancer-Specific Survival (CSS) Recurrence-Free Survival (RFS) Objective Response Rate (ORR) Treatment duration, line, sequence, and dose modifications during systemic therapy Treatment discontinuation and reasons for discontinuation Treatment tolerability and adverse event profile graded according to CTCAE version 5.0 | — |
Countries
Austria, Germany, Switzerland
Contacts
Public ContactJozefina Casuscelli
Urologische Klinik und Poliklinik, LMU Klinikum
Outcome results
None listed